FDx Advisors Inc. purchased a new position in Omnicell Technologies (NASDAQ:OMCL) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 6,685 shares of the company’s stock, valued at approximately $290,000.
Several other hedge funds have also recently added to or reduced their stakes in OMCL. Elkfork Partners LLC purchased a new position in shares of Omnicell Technologies in the 4th quarter worth $225,000. Xact Kapitalforvaltning AB purchased a new position in Omnicell Technologies during the fourth quarter valued at $244,000. Stone Ridge Asset Management LLC purchased a new position in Omnicell Technologies during the fourth quarter valued at $360,000. USA Financial Portformulas Corp purchased a new position in Omnicell Technologies during the fourth quarter valued at $364,000. Finally, Shelton Capital Management lifted its position in Omnicell Technologies by 17.6% during the fourth quarter. Shelton Capital Management now owns 9,800 shares of the company’s stock valued at $475,000 after purchasing an additional 1,464 shares in the last quarter.
NASDAQ OMCL opened at $46.20 on Friday. The firm has a market cap of $1.81 billion, a P/E ratio of 256.67, a P/E/G ratio of 2.14 and a beta of 0.76. The company has a current ratio of 1.68, a quick ratio of 1.22 and a debt-to-equity ratio of 0.33. Omnicell Technologies has a fifty-two week low of $46.00 and a fifty-two week high of $46.45.
Several research firms recently weighed in on OMCL. BidaskClub downgraded Omnicell Technologies from a “hold” rating to a “sell” rating in a research report on Friday, April 20th. Craig Hallum downgraded Omnicell Technologies from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Cantor Fitzgerald reiterated a “buy” rating and set a $63.00 target price on shares of Omnicell Technologies in a research report on Tuesday, April 3rd. Piper Jaffray lifted their target price on Omnicell Technologies from $38.00 to $44.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. Finally, Oppenheimer reiterated a “buy” rating and set a $55.00 target price on shares of Omnicell Technologies in a research report on Monday, January 29th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $56.67.
In other Omnicell Technologies news, insider Peter J. Kuipers sold 3,456 shares of the firm’s stock in a transaction dated Friday, May 11th. The stock was sold at an average price of $47.62, for a total transaction of $164,574.72. Following the sale, the insider now directly owns 56,970 shares of the company’s stock, valued at $2,712,911.40. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Robin Gene Seim sold 13,286 shares of the firm’s stock in a transaction dated Tuesday, May 15th. The shares were sold at an average price of $46.48, for a total value of $617,533.28. Following the sale, the insider now directly owns 74,121 shares in the company, valued at $3,445,144.08. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,161 shares of company stock worth $1,786,193. Insiders own 3.71% of the company’s stock.
Omnicell Technologies Company Profile
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Receive News & Ratings for Omnicell Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Technologies and related companies with MarketBeat.com's FREE daily email newsletter.